M&A

Viatris completes $1.6B Pacira buy to grow beyond generics

What's the deal? ViatrisDealroom has a profile for this one. Try Dealroom → has completed its $1.6 billion cash acquisition of Pacira BioSciences, first announced in October at $36.50 per share. The purchase adds EXPAREL and ZILRETTA, two established non-opioid pain medicines, to Viatris's portfolio.

What's the endgame? The deal is a concrete step in Viatris's stated push to grow its innovative-medicines business beyond its legacy generics base. Rather than a speculative pipeline bet, this is a purchase of commercial products and capabilities.

Why now? Pacira reported trailing-12-month revenue of $746 million and adjusted EBITDA of $177 million in Viatris's deal materials. That gives Viatris immediate revenue, not just future promise.

The signal: The acquisition fits a broader 2026 pattern of drugmakers using M&A to diversify portfolios, though at a smaller scale than several multibillion-dollar transactions this year. For Viatris, it marks a shift from generic volume toward branded, higher-margin medicines.

Read more: bizjournals.com

Image credit: Generated with Gemini

More top stories